ドルゾラミドからブリンゾラミドへの切り替え試験後の眼圧下降効果の比較

Ocular hypotensive effect of brinzolamide after switching from dorzolamide

　目的：ドルゾラミド1％点眼液とブリンゾラミド1％点眼液の眼圧下降効果の比較。対象と方法：ドルゾラミドを含む多剤併用で6か月以上眼圧が安定している原発開放隅角緑内障患者30例30眼を対象とした。男性と女性各15例で，年齢は32～87歳，平均64.2±13.3歳であった。患者の同意を得てドルゾラミド継続群15例とブリンゾラミド切り替え群15例に無作為に分け，両群の切り替え前後3か月間の眼圧平均値と，切り替え前後で同時期に測定した各1か月ごとの眼圧平均値を比較した。結果：実験開始前3か月間の眼圧平均値は，ドルゾラミド継続群が15.4±2.4mmHg，ブリンゾラミド切り替え群が15.6±3.6mmHgであった。両群間で，切り替え前後3か月間の平均眼圧値と，同時期の眼圧経過に有意差はなかった。結論：ドルゾラミド点眼液とブリンゾラミド点眼液には同等の眼圧下降効果がある。

　Purpose：To compare the ocular hypotensive effect of 1％brinzolamide and dorzolamide ophthalmic solutions. Cases and Methods：A prospective study was conducted on 30 eyes of 30 patients of primary open-angle glaucoma. The series comprised 15males and 15 females. Their ages ranged from 32 to 87 years,average 64.2±13.3 years. All the eyes had well-controlled intraocular pressure（IOP）during the previous 6months under treatments including dorzolamide. The 30 eyes were divided into two groups. One group switched to brinzolamide from dorzolamide. The other group continued the previous medications including dorzolamide and served as control. The average IOP level was calculated in both groups during 3months before and after start of the study. Tonometry was also performed in both groups at one-month intervals. Results：IOP during 3months before start of the study averaged 15.6±3.6mmHg in brinzolamide group and 15.4±2.4mmHg in control group. There were no significant differences between the two groups regarding IOP before and after start of study. Conclusion：Brinzolamide and dorzolamide have equal ocular hypotensive effect.